Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Durvalumab market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Durvalumabmarket, defines the market attractiveness level of Durvalumab market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Durvalumab industry, describes the types of Durvalumab market, the applications of major players and the market size, and deeply analyzes the current situation of the global Durvalumab market and the development prospects and opportunities of Durvalumab industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Durvalumab market in Chapter 13.
By Player:
Medimmune (AstraZeneca)
By Type:
24mL Injection
10mL Injection
By End-User:
Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Other
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Durvalumab Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Durvalumab Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Durvalumab Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Durvalumab Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Durvalumab Market Analysis and Outlook to 2022
-
7.1 Global Durvalumab Consumption (2017-2022)
-
7.2 United States Durvalumab Consumption (2017-2022)
-
7.3 Europe Durvalumab Consumption (2017-2022)
-
7.4 China Durvalumab Consumption (2017-2022)
-
7.5 Japan Durvalumab Consumption (2017-2022)
-
7.6 India Durvalumab Consumption (2017-2022)
-
7.7 South Korea Durvalumab Consumption (2017-2022)
8 Region and Country-wise Durvalumab Market Analysis and Outlook to 2028
-
8.1 Global Durvalumab Consumption Forecast (2022-2028)
-
8.2 United States Durvalumab Consumption Forecast (2022-2028)
-
8.3 Europe Durvalumab Consumption Forecast (2022-2028)
-
8.4 China Durvalumab Consumption Forecast (2022-2028)
-
8.5 Japan Durvalumab Consumption Forecast (2022-2028)
-
8.6 India Durvalumab Consumption Forecast (2022-2028)
-
8.7 South Korea Durvalumab Consumption Forecast (2022-2028)
9 Global Durvalumab Market Outlook by Types and Applications to 2022
-
9.1 Global Durvalumab Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global 24mL Injection Consumption and Growth Rate (2017-2022)
-
9.1.2 Global 10mL Injection Consumption and Growth Rate (2017-2022)
-
9.2 Global Durvalumab Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Locally Advanced Urothelial Carcinoma Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Metastatic Urothelial Carcinoma Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Other Consumption and Growth Rate (2017-2022)
10 Global Durvalumab Market Outlook by Types and Applications to 2028
-
10.1 Global Durvalumab Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global 24mL Injection Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global 10mL Injection Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Durvalumab Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Locally Advanced Urothelial Carcinoma Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Metastatic Urothelial Carcinoma Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)
11 Global Durvalumab Import and Export Analysis (Top 5 Countries)
-
11.1 Global Durvalumab Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Durvalumab Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Durvalumab Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Durvalumab Market Competitive Analysis
-
14.1 Medimmune (AstraZeneca)
-
14.1.1 Medimmune (AstraZeneca) Company Details
-
14.1.2 Medimmune (AstraZeneca) Durvalumab Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Medimmune (AstraZeneca) Durvalumab Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Durvalumab
-
Figure Durvalumab Picture
-
Table Global Durvalumab Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Durvalumab Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Durvalumab Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Durvalumab Consumption by Country (2017-2022)
-
Figure United States Durvalumab Consumption and Growth Rate (2017-2022)
-
Table Europe Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure China Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Japan Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure India Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure South Korea Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Global Durvalumab Consumption Forecast by Country (2022-2028)
-
Figure United States Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global 24mL Injection Consumption and Growth Rate (2017-2022)
-
Figure Global 10mL Injection Consumption and Growth Rate (2017-2022)
-
Figure Global Locally Advanced Urothelial Carcinoma Consumption and Growth Rate (2017-2022)
-
Figure Global Metastatic Urothelial Carcinoma Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global 24mL Injection Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global 10mL Injection Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Locally Advanced Urothelial Carcinoma Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Metastatic Urothelial Carcinoma Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Durvalumab Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Durvalumab Export by Region (Top 5 Countries) (2017-2028)
-
Table Medimmune (AstraZeneca) (Foundation Year, Company Profile and etc.)
-
Table Medimmune (AstraZeneca) Durvalumab Sales, Price, Value and Gross Profit (2017-2022)
-
Table Medimmune (AstraZeneca) Durvalumab Product and Service
-
